hyperparathyroidism: Hyperfunction of the parathyroid glands resulting in the overproduction of parathyroid hormone. It may be primary or secondary; primary hyperparathyroidism is caused by parathyroid adenoma, parathyroid hyperplasia, parathyroid carcinoma, and multiple endocrine neoplasia. It is associated with hypercalcemia and hypophosphatemia. Signs and symptoms include weakness, fatigue, nausea, vomiting, constipation, depression, bone pain, osteoporosis, cystic bone lesions, and kidney stones. Secondary hyperparathyroidism is caused by the chronic stimulation of the parathyroid glands in patients with chronic renal failure, rickets, and malabsorption syndromes.

Endpoint definition

FinnGen phenotype data
diagram bullet diagram downward connector

Filter registries Inpat., Oupat., Death, KELA purch., KELA reimb.

Hospital Discharge: ICD-10 E21.09, E21.1, E21.2, E21.3
Hospital discharge: ICD-9 2520
Hospital discharge: ICD-8 2520
Cause of death: ICD-10 E21.09, E21.1, E21.2, E21.3
Cause of death: ICD-9 2520
Cause of death: ICD-8 2520
Medicine purchases: ATC H05B
Medicine purchases: ATC: other data required >3 instances required

Check pre-conditions None

Include endpoints None

Check conditions None

Apply sex-specific rule None

diagram downward connector E4_HYPERPARA

Extra metadata

Level in the ICD hierarchy 4
First used in FinnGen datafreeze DF2

Summary Statistics

Key figures

All Female Male
Number of individuals 3602 2691 911
Unadjusted prevalence (%) 1.39 1.83 0.81
Mean age at first event (years) 62.85 62.99 62.44


Follow-up Absolute risk HR [95% CI] p N
1998–2019 0.04 2.91 [2.28, 3.71] 5.3e-18 796
15 years 0.02 3.15 [2.57, 3.86] 2.4e-28 707
5 years - - - -
1 year - - - -


Index endpoint: E4_HYPERPARA – Hyperparathyroidism
GWS hits: 2

Survival analyses between endpoints


before Hyperparathyroidism
after Hyperparathyroidism

loading spinner Loading survival analyses plot

Drugs most likely to be purchased after Hyperparathyroidism